09.12.2009 • NewsDSM

Yield Boosts for Mammalian Manufacturing Platforms

DSM announced that its proprietary XD Technology boosts bioreactor productivity and titers of mammalian cell culture processes by 5 - 10 fold for the production of proteins and antibodies. Recent studies completed at the R&D labs of DSM Biologics in Groningen, The Netherlands, demonstrated that the yields from CHO-based cell cultures can be increased 5 - 10 fold over their previous fed-batch processes using only off the shelf, commercially available media. The XD Technology has been tested for antibody and recombinant protein production across multiple cell lines, and the increase was realized in all cases.


Jaap Schilder, Site Director Groningen, comments, "This opens the door to a completely novel way of supplying drug substance for clinical trials and for market needs. The XD process increases the overall output of a facility dramatically and the process ­duration and handling is similar to any fed-batch process." DSM is currently working with multiple customers at the Groningen site for XD process ­development. They are booking development slots now for 2010.

Company

DSM Pharmaceutical Products

45 Waterview Blvd.
Parsippany, NJ 07054-1298

Company contact







CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Free Virtual Event

ProteiNext 2025

ProteiNext 2025

ProteiNext is an annual symposium that offers a platform for sharing insights on protein analysis